New visions in the pharmacology of anticonvulsion

European Journal of Pharmacology

Volumn 342, Issue 1, 1998, Pages 1-13

  Löscher, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Antiepileptic drug; Epilepsy; GABA( aminobutyric acid); Glutamate; Seizure

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BRETAZENIL; CARBAMAZEPINE; DIZOCILPINE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; GABOXADOL; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXCARBAZEPINE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROGABIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; CONVULSION; DRUG EFFICACY; EPILEPTOGENESIS; HUMAN; KINDLING; NERVE CELL EXCITABILITY; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE;

ANIMALS; ANTICONVULSANTS; DRUG DESIGN; EPILEPSY; HUMANS;

EID: 0345019797     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01514-8     Document Type: Review

References (82)

1. Allen K.M., Walsh C. Shaking down new epilepsy genes. Nature Med. 2:1996;516-518.
2. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference. Epilepsy Res. 25:1996;299-319.
3. Brodie M.J., Yuen A.W.C. Lamotrigine substitution study: Evidence for synergism with sodium valproate? Epilepsy Res. 26:1997;423-432.
4. Chadwick D.W. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia. 38:1997;S59-S62.
5. Commission on Classification and Terminology of the International League Against Epilepsy, 1981. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22, 489-501.
6. Commission on Classification and Terminology of the International League Against Epilepsy, 1989. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30, 389-399.
7. Costa E., Guidotti A. Benzodiazepines on trial: A research strategy for their rehabilitation. Trends Pharmacol. Sci. 17:1996;192-200.
8. Dam, M., 1986. Intractable epilepsy: Introduction. In: Schmidt, D., Morselli, P.L. (Eds.), Intractable Epilepsy: Experimental and Clinical Aspects. Raven Press, New York, pp. 1-3.
9. Dam M. Epilepsy surgery. Acta Neurol. Scand. 94:1996;81-87.
10. Dichter M.A. Emerging insights into mechanisms of epilepsy: Implications for new antiepileptic drug development. Epilepsia. 35:1994;S51-S57.
11. Dingledine R., McBain C.J., McNamara J.O. Excitatory amino acid receptors in epilepsy. Trends Pharmacol. Sci. 11:1990;334-338.
12. Dreifuss, F.E., 1992. Present status in the treatment of the epilepsies. In: Theodore, W.H. (Ed.), Surgical Treatment of Epilepsy. Elsevier, Amsterdam, pp. 3-5.
13. Engel, J.J., 1992. Experimental models of epilepsy: classification and relevance to human epileptic phenomena. In: Avanzini, G., Engel, J.J., Fariello, R. and Heinemann, U. (Eds.), Neurotransmitters in Epilepsy. Elsevier, Amsterdam, pp. 9-20.
14. Forsgren, L., 1995. Epidemiology of intractable epilepsy in adults. In: Johannessen, S.I., Gram, L., Sillanpää, M., Tomson, T. (Eds.), Intractable Epilepsy. Wrightson Biomedical Publishing, Petersfield, pp. 25-40.
15. Fredholm B., Abbott A. New targets for drug action: Is high selectivity always beneficial? Trends Pharmacol. Sci. 11:1990;175-178.
16. Grant S.M., Heel R.C. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 41:1991;889-926.
17. Haria M., Balfour J.A. Levetiracetam. Cns. Drugs. 7:1997;159-164.
18. Heinemann U., Draguhn A., Ficker E., Stabel J., Zhang C.L. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia. 35:1994;S10-S21.
19. Hernandez T.D. Preventing post-traumatic epilepsy after brain injury: Weighing the costs and benefits of anticonvulsant prophylaxis. Trends Pharmacol. Sci. 38:1997;59-62.
20. Hosford D.A., Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia. 38:1997;408-414.
21. Leccese A.P., Marquis K.L., Mattia A., Moreton J.E. The convulsant and anticonvulsant effects of phencyclidine (PCP) and PCP analogues in the rat. Behav. Brain Res. 19:1988;163-169.
22. Lees G.J. Therapeutic potential of AMPA receptor ligands in neurological disorders. Cns. Drugs. 5:1996;51-74.
23. Leppik, I.E., 1992. Intractable epilepsy in adults. In: Theodore, W.H. (Ed.), Surgical Treatment of Epilepsy. Elsevier, Amsterdam, pp. 7-11.
24. Leppik, I.E., 1996. Rational Polypharmacy. Elsevier, Amsterdam.
25. Lindvall O., Björklund A. Intracerebral grafting of inhibitory neurons. A new strategy for seizure suppression in the central nervous system. Adv. Neurol. 57:1992;561-569.
26. Loiseau, P. (1986) Intractable epilepsy: prognostic evaluation. In: Schmidt, D. and Morselli, P.L. (Eds.), Intractable Epilepsy: Experimental and Clinical Aspects. Raven Press, New York, NY, pp. 227-258.
27. Lothman E.W. Basic mechanisms of seizure spread. Epilepsy Res. 11 (Suppl.):1996;9-16.
28. Löscher, W., 1986. Development of tolerance to the anticonvulsant effect of GABA-mimetic drugs in animal models of seizure states. In: Frey, H.-H., Fröscher, W., Koella, W.P., Meinardi, H. (Eds.), Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. Raven Press, New York, pp. 37-45.
29. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 501:1989;198-203.
30. Löscher, W., 1989b. GABA and the epilepsies. Experimental and clinical considerations. In: Bowery, N.G., Nisticò, G. (Eds.), GABA. Basic Research and Clinical Applications. Pythagora Press, Rome, pp. 260-300.
31. Löscher W. Basic aspects of epilepsy. Curr. Opin. Neurol. Neurosurg. 6:1993;223-232.
32. Löscher, W., 1997a. Animal models of epilepsy and epileptic seizures. In: Eadie, M.J., Vajda, F. (Eds.), Antiepileptic Drugs. Handbook of Experimental Pharmacology. Springer, Berlin. In press.
33. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 53:1997;239-258.
34. Löscher W., Ebert U. Basic mechanisms of seizure propagation: Targets for rational drug design and rational polypharmacy. Epilepsy Res. 11 (Suppl.):1996;17-44.
35. Löscher W., Hönack D. High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats. Naunyn-Schmiedebergs Arch. Pharmacol. 341:1990;476-481.
36. Löscher W., Hönack D. Responses to NMDA receptor antagonists altered by epileptogenesis. Trends Pharmacol. Sci. 12:1991;52.
37. Löscher W., Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: Selection of phenytoin-resistant and nonresistant rats. J. Pharmacol. Exp. Ther. 258:1991;483-489.
38. Löscher W., Schmidt D. Increase of human plasma GABA by sodium valproate. Epilepsia. 21:1980;611-615.
39. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2:1988;145-181.
40. Löscher W., Schmidt D. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation? Epilepsy Res. 17:1994;95-134.
41. Löscher, W., Wauquier, A., 1996. Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res. (Suppl.), 61-65.
42. Löscher W., Hönack D., Taylor C.P. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci. Lett. 128:1991;150-154.
43. Löscher W., Gram L., Stefan H. Plasma GABA and seizure control with vigabatrin. Lancet. 341:1993;117.
44. Löscher W., Rundfeldt C., Hönack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 5:1993;1545-1550.
45. Löscher W., Rundfeldt C., Hönack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 15:1993;207-219.
46. Löscher W., Fassbender C.P., Gram L., Gramer M., Hörstermann D., Zahner B., Stefan H. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: Correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res. 14:1993;245-255.
47. Löscher, W., Hönack, D., Rundfeldt, C., 1997a. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. In press.
48. Löscher, W., Ebert, U., Lehmann, H., Rosenthal, C., Nikkhah, G., 1997b. Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra. J. Neurosci. Res. In press.
49. Macdonald R.L. Antiepileptic drug action. Epilepsia. 30(1):1989;S19-S28.
50. Macdonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia. 36:1995;S2-S12.
51. Macdonald, R.L., Meldrum, B.S., 1995. Principles of antiepileptic drug action. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs, 4th ed. Raven Press, New York, pp. 61-78.
52. Marescaux C., Vergnes M., Depaulis A. Genetic absence epilepsy in rats from Strasbourg: A review. J. Neural Transm. 35:1992;37-69.
53. Mattson, R.H., 1995. Selection of antiepileptic drug therapy. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs, 4th ed. Raven Press, New York, pp. 123-136.
54. McNamara J.O. Cellular and molecular basis of epilepsy. J. Neurosci. 14:1994;3413-3425.
55. Meldrum B. Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy. Epilepsy Res. 11 (Suppl.):1996;67-78.
56. Olsen R.W., Avoli M. GABA and epileptogenesis. Epilepsia. 38:1997;399-407.
57. Pellock J.M. Antiepileptic drug therapy in the United States: A review of clinical studies and unmet needs. Neurology. 45:1995;S17-S24.
58. Perucca E. The new generation of antiepileptic drugs: Advantages and disadvantages. Br. J. Clin. Pharmacol. 42:1996;531-543.
59. Petroff O.A.C., Rothman D.L., Behar K.L., Collins T.L., Mattson R.H. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology. 47:1996;1567-1571.
60. Petroff O.A.C., Rothman D.L., Behar K.L., Lamoureux D., Mattson R.H. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann. Neurol. 39:1996;95-99.
61. Richens, A., 1991. The efficacy and safety of new antiepileptic drugs. In: Pisani, F., Perucca, E., Avanzini, G., Richens, A. (Eds.), New Antiepileptic Drugs. Elsevier, Amsterdam, pp. 89-96.
62. Rogawski M.A., Porter R.J. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286.
63. Rogvihansen B.A., Gram L. Adverse effects of established and new antiepileptic drugs: An attempted comparison. Pharmacol. Ther. 68:1995;425-434.
64. Sabers A., Gram L. Drug treatment of epilepsy in the 1990s: Achievements and new developments. Drugs. 52:1996;483-493.
65. Schachter S.C. Review of the mechanisms of action of antiepileptic drugs. Cns. Drugs. 4:1995;469-477.
66. Scheuer M.L., Pedley T.A. The evaluation and treatment of seizures. N. Engl. J. Med. 323:1990;1468-1474.
67. Schmidt, D., 1997. Search for new anticonvulsants. In: Eadie, M.J., Vajda, F. (Eds.), Antiepileptic Drugs. Handbook of Experimental Pharmacology. Springer, Berlin. In press.
68. Schmidt D., Gram L. Monotherapy versus polytherapy in epilepsy: A reappraisal. Cns. Drugs. 3:1995;194-208.
69. Schmidt D., Krämer G. The new anticonvulsant drugs. Implications for avoidance of adverse effects. Drug Safety. 11:1994;422-431.
70. Shinnar S., Berg A.T. Does antiepileptic drug therapy prevent the development of 'chronic' epilepsy? Epilepsia. 37:1996;701-708.
71. Sillanpää, M., 1995. Epidemiology of intractable epilepsy in children. In: Johannessen, S.I., Gram, L., Sillanpää, M., Tomson, T. (Eds.), Intractable Epilepsy. Wrightson Biomedical Publishing, Petersfield, pp. 13-25.
72. Squires R.F., Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: More support for a continuum hypothesis of 'functional' psychosis. Neurochem. Res. 16:1991;1099-1111.
73. Taylor, C.P., 1995. Gabapentin. Mechanisms of action. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs, 4th ed. Raven Press, New York, pp. 829-841.
74. Taylor C.P., Vartanian M.G., Andruszkiewiewicz R., Silverman R.B. 3-Alkyl GABA and 3-alkylglutamic acid analogues: Two new classes of anticonvulsant agents. Epilepsy Res. 11:1992;103-110.
75. Theodore, W.H., 1992. National Institutes of Health Consensus Development Conference Statement: Surgery for Epilepsy (19-21 March 1990). In: Theodore, W.H. (Ed.), Surgical Treatment of Epilepsy. Elsevier, Amsterdam, pp. 241-246.
76. Thomas L., Trimble M., Schmitz B., Ring H. Vigabatrin and behaviour disorders: A retrospective survey. Epilepsy Res. 25:1996;21-27.
77. Turner, J.D., Bodewitz, G., Thompson, C.L., Stephenson, F.A., 1993. Immunohistochemical mapping of gamma-aminobutyric acid type A receptor alpha subunits in rat central nervous system. In: Stephens, D.N. (Ed.), Anxiolytic β-carbolines: From Molecular Biology to the Clinic. Springer-Verlag, Berlin, pp. 29-49.
78. Upton N. Mechanisms of action of new antiepileptic drugs: Rational design and serendipitous findings. Trends Pharmacol. Sci. 15:1994;456-463.
79. Waldmeier P.C., Martin P., Stocklin K., Portet C., Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn-Schmiedebergs Arch. Pharmacol. 354:1996;164-172.
80. White H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 38:1997;S9-S17.
81. Wlaz, P., Löscher, W., 1997. Evaluation of associated behavioral and cognitive deficits in anticonvulsant drug testing. In: Peterson, S., Albertson, T. (Eds.), Neuropharmacology Methods in Epilepsy Research. CRC Press, Boca Raton. In press.
82. Wlaz P., Ebert U., Löscher W. Low doses of the glycine/NMDA receptor antagonist R-(+)-HA-966 but not D-cycloserine induce paroxysmal activity in limbic brain regions of kindled rats. Eur. J. Neurosci. 6:1994;1710-1719.